ARID4B, AT-rich interaction domain 4B, 51742

N. diseases: 62; N. variants: 0
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0011860
Disease: Diabetes Mellitus, Non-Insulin-Dependent
Diabetes Mellitus, Non-Insulin-Dependent 		0.070 Biomarker disease BEFREE Weighted Co-expression Networks Analysis provided support to idea that the BCAA genes are relevant in the pathophysiology of type 2 diabetes, and that mitochondrial BCAA management is impaired in skeletal muscle from T2D patients. 29062026 2017
CUI: C0154246
Disease: Urea Cycle Disorders, Inborn
Urea Cycle Disorders, Inborn 		0.020 AlteredExpression group BEFREE We studied the correlations between plasma L-arginine levels, plasma branched chain amino acids (BCAA: L-isoleucine, L-leucine and L-valine) levels (amino acids known to influence growth), and height in MMA/PA and UCD patients. 30827756 2019
CUI: C0268579
Disease: Propionic acidemia
Propionic acidemia 		0.010 AlteredExpression disease BEFREE We studied the correlations between plasma L-arginine levels, plasma branched chain amino acids (BCAA: L-isoleucine, L-leucine and L-valine) levels (amino acids known to influence growth), and height in MMA/PA and UCD patients. 30827756 2019
CUI: C0276096
Disease: Mastitis-metritis-agalactia syndrome
Mastitis-metritis-agalactia syndrome 		0.010 AlteredExpression disease BEFREE We studied the correlations between plasma L-arginine levels, plasma branched chain amino acids (BCAA: L-isoleucine, L-leucine and L-valine) levels (amino acids known to influence growth), and height in MMA/PA and UCD patients. 30827756 2019
CUI: C0221074
Disease: Depression, Postpartum
Depression, Postpartum 		0.010 Biomarker disease BEFREE We investigated whether perinatal consumption of a Western-type diet (high in fat and branched-chain amino acids [BCAA]) and associated gestational weight gain (GWG) cause serotonin dysregulation in the central nervous system (CNS), resulting in postpartum depression and anxiety (PPD/A). 29075574 2017
CUI: C1510586
Disease: Autism Spectrum Disorders
Autism Spectrum Disorders 		0.010 AlteredExpression disease BEFREE We identified groups of AAs with positive correlations that were, as a group, negatively correlated with BCAA levels in ASD. 30446206 2019
CUI: C0011860
Disease: Diabetes Mellitus, Non-Insulin-Dependent
Diabetes Mellitus, Non-Insulin-Dependent 		0.070 Biomarker disease BEFREE We hypothesized that plasma BCAAs are positively associated with CVD risk and evaluated whether this was dependent on an intermediate diagnosis of T2D. 29572205 2018
CUI: C0020459
Disease: Hyperinsulinism
Hyperinsulinism 		0.010 Biomarker disease BEFREE We conclude that a decrease in mitochondrial BCAA degradation and an increase in inflammation in SAT co-occur and associate with hyperinsulinemia and large adipocyte size in unhealthy obesity. 28439093 2017
CUI: C0023890
Disease: Liver Cirrhosis
Liver Cirrhosis 		0.020 Biomarker disease BEFREE We conclude that (1) HMB supplementation has a positive effect on muscle mitochondrial function and enhances BCAA concentrations in healthy animals and (2) the effects of HMB on the course of liver cirrhosis in CCl4-treated rats are detrimental. 31321841 2019
CUI: C0011847
Disease: Diabetes
Diabetes 		0.030 Biomarker disease BEFREE This article reveals the mechanism of BCAA-induced insulin resistance and the relationship between exercise and BCAAs metabolism, adds a guarantee for the use of BCAAs, and provides a new explanation for the occurrence of diabetes and how exercise improves diabetes. 31666474 2019
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus 		0.030 Biomarker group BEFREE This article reveals the mechanism of BCAA-induced insulin resistance and the relationship between exercise and BCAAs metabolism, adds a guarantee for the use of BCAAs, and provides a new explanation for the occurrence of diabetes and how exercise improves diabetes. 31666474 2019
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.050 Biomarker disease BEFREE These studies support a causative role of ARID4B in metastatic progression of breast cancer. 22693453 2012
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.050 Biomarker disease BEFREE These studies support a causative role of ARID4B in metastatic progression of breast cancer. 22693453 2012
CUI: C4529962
Disease: Fatty Liver Disease
Fatty Liver Disease 		0.010 GeneticVariation disease BEFREE These cumulative alterations in BCAA metabolite and amino acid metabolism gene profiles represent adaptive physiological responses to disease-induced hepatic stress in NASH patients. 25534430 2015
CUI: C0750974
Disease: Brain Tumor, Primary
Brain Tumor, Primary 		0.010 Biomarker disease BEFREE Therefore, ARID4B is a satisfactory biomarker to highlight tumour component and predict tumour behaviour in primary brain neoplasms. 27451434 2017
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.040 Biomarker group BEFREE Therefore, ARID4B is a satisfactory biomarker to highlight tumour component and predict tumour behaviour in primary brain neoplasms. 27451434 2017
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.040 Biomarker group BEFREE The two potential markers brcaa1 and ndr1 identified may be used to distinguish cancer status fand non-cancer status. 15761963 2005
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.030 Biomarker group BEFREE The two potential markers brcaa1 and ndr1 identified may be used to distinguish cancer status fand non-cancer status. 15761963 2005
CUI: C0022661
Disease: Kidney Failure, Chronic
Kidney Failure, Chronic 		0.010 Biomarker disease BEFREE The studies indicate beneficial effects of BCAAs and BCKAs in therapy of chronic renal failure. 29755574 2018
CUI: C1561643
Disease: Chronic Kidney Diseases
Chronic Kidney Diseases 		0.010 Biomarker group BEFREE The studies indicate beneficial effects of BCAAs and BCKAs in therapy of chronic renal failure. 29755574 2018
CUI: C2316810
Disease: Chronic kidney disease stage 5
Chronic kidney disease stage 5 		0.010 Biomarker disease BEFREE The studies indicate beneficial effects of BCAAs and BCKAs in therapy of chronic renal failure. 29755574 2018
CUI: C0400966
Disease: Non-alcoholic Fatty Liver Disease
Non-alcoholic Fatty Liver Disease 		0.010 AlteredExpression disease BEFREE The purpose of this study is to profile changes in hepatic BCAA metabolite levels with transcriptomic changes in the progression of human NAFLD to discover novel mechanisms of disease progression. 25534430 2015
CUI: C0010606
Disease: Adenoid Cystic Carcinoma
Adenoid Cystic Carcinoma 		0.300 Biomarker disease CTD_human The mutational landscape of adenoid cystic carcinoma. 23685749 2013
CUI: C3160854
Disease: Small intestinal bacterial overgrowth
Small intestinal bacterial overgrowth 		0.010 GeneticVariation disease BEFREE The metabolic pathways of BCAA and/or their metabolites correlated with excess of visceral fat centimeters (leucine/oxo-valerate), and more deranged IP and SIBO (valine metabolites). 28492501 2017
CUI: C0015230
Disease: Exanthema
Exanthema 		0.010 Biomarker phenotype BEFREE The skin rashes resolved after adding BCAAs and adjusting the infant formula. 24486081 2016